Research Article

Clinicopathological Features of 166 Cases of Invasive Ductal Breast Carcinoma and Effect of Primary Tumor Location on Prognosis after Modified Radical Mastectomy

Shiman Chen, Liang Yang, and Yaqiong Li

Department of Thyroid and Breast and Vascular Surgery, Renmin Hospital, Hubei University of Medicine, Shiyan, Hubei 442000, China

Correspondence should be addressed to Yaqiong Li; satan_1023@126.com

Received 21 March 2022; Accepted 20 May 2022; Published 18 June 2022

Academic Editor: Weiguo Li

Copyright © 2022 Shiman Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Objective. To investigate the clinicopathological features of 166 cases of invasive ductal carcinoma (IDC) of the breast and to analyze the effect of the location of the primary tumor on the prognosis of modified radical mastectomy. Materials and Methods. The clinical data of 166 patients with IDC who underwent modified radical mastectomy in our hospital from May 2015 to May 2017 were retrospectively analyzed. The clinicopathological features of IDC patients were recorded. Univariate analysis and the multivariate logistic regression model were used to analyze the relationship between the location of the primary tumor and the prognosis of IDC patients after modified radical surgery. The effect of primary tumor location on the prognosis of modified radical resection was used with Survival curve analysis. Results. Among the patients in the central region, 13.33% had tumors > 5 cm in diameter, which was higher than those in the other four groups. Among the patients in the upper inner quadrant, 59.38% received hormone therapy after operation, which was higher than those in the other four groups \( P < 0.05 \). There were no significant differences in age, menopause, histological grading, molecular typing, lymph node metastasis, vascular invasion, radiation therapy, and chemotherapy among different groups \( P > 0.05 \). Univariate analysis showed that molecular typing, lymph node metastasis, vascular invasion, and chemotherapy among different groups \( P > 0.05 \). Logistic regression analysis showed that molecular typing, lymph node metastasis, vascular invasion, and location of the primary tumor were all related to the prognosis of IDC patients after modified radical surgery, and the differences were statistically significant \( P < 0.05 \). Logistic regression analysis showed that molecular typing, lymph node metastasis, vascular invasion, and primary tumor location were all independent influencing factors for prognosis of IDC patients after modified radical surgery \( P < 0.05 \). As of 31 May 2021, there were 11 patients with recurrence and metastasis and 20 patients with death. The median survival time in the outer upper quadrant group was 80 months, which was higher than that in the outer lower quadrant group by 72 months, the median survival time in the inner upper quadrant group by 67 months, and the median survival time in the inner lower quadrant group by 61 months. The log-rank test showed all \( P < 0.001 \). Conclusion. Patients with primary tumors located in the central area have larger tumor diameters. Patients located in the central area, upper inner quadrant, and lower inner quadrant are more likely to have lymphatic metastasis, have a more serious condition, and have a shorter prognosis survival time. Unluminal type, multiple lymph node metastases, vascular invasion, and the location of the primary tumor in the inner quadrant are all independent risk factors for prognosis in patients after modified radical surgery for IDC.

1. Introduction

Breast cancer is one of the most common malignancies in women. In recent years, its incidence has been increasing year by year in the global scope. Invasive ductal carcinoma (IDC) of the breast is the most common type of breast cancer and belongs to nonspecific invasive carcinoma of the breast. Clinically, patients often have breast lumps and nipple discharge [1, 2]. IDC often affects the physical and psychological health of women due to the younger onset group, the tendency of lymphatic metastasis and recurrence in advanced patients, and the influence on the appearance of...
breasts after surgical resection [3, 4]. Therefore, early diagnosis and treatment of IDC are extremely important.

At present, the treatment methods for IDC mainly include radical surgery, modified radical surgery, and postoperative chemoradiotherapy [5, 6]. Among them, modified radical surgery is an effective method for the treatment of IDC. It can preserve the pectoralis minor and pectoralis major muscles of the affected side of the patient and minimize the damage to the shape of the breast. Compared with traditional surgery, modified radical surgery not only ensures the thoroughness of tumor resection but also satisfies the pursuit of beauty for female patients. It is the most commonly used surgical method in clinical practice at present. [7, 8]. With the nipple as the center, the breast can be divided into five positions, including four quadrants and a central area. The primary tumor is located in different locations, and the progression speed of the disease is also different. In this study, we retrospectively analyzed the follow-up data of 166 IDC patients within five years after modified radical surgery, summarized the clinicopathologic features of these patients, and analyzed the impact of the location of primary tumors on the prognosis of modified radical surgery. The specific report is as follows.

2. Information and Methods

2.1. General Information. A total of 166 IDC patients undergoing modified radical mastectomy in our hospital from May 2015 to May 2017 were retrospectively collected. Their age ranged from 25 to 75 years old, with an average of 50.79 ± 9.61 years old.

2.2. Inclusion Criteria. Inclusion criteria were as follows: (1) Meets breast cancer IDC diagnostic criteria; (2) pathological diagnosis is unilateral IDC; (3) receiving modified radical mastectomy; (4) having complete clinical and pathological data and follow-up information.

2.3. Exclusion Criteria. Exclusion criteria were as follows: (1) Preoperative neoadjuvant chemotherapy; (2) distant metastasis has occurred at the time of initial treatment; (3) the location of the tumor is located in the boundary area of each quadrant; (4) multifocal breast cancer; (5) male breast cancer.

2.4. Primary Tumor Location. Tumor location was determined on the basis of a preoperative imaging report (color Doppler ultrasound, mammography, or MRI) closest to the date of surgery and intraoperative measurements. A horizontal and vertical line was drawn with the nipple as the center, which divided the breast into outer upper, outer lower, inner upper, and inner lower. The nipple and areola were the central area, 5 regions in total. The location of the primary tumor was divided into the outer upper quadrant, the outer lower quadrant, the inner upper quadrant, the inner lower quadrant, and the central region, which included the nipples and areola complex.

2.5. Postoperative Follow-Up. A follow-up was performed every 3 months for the 2-year postoperative period, semiannually from the 3rd year, and annually after the 5th year. The follow-up included breast tumor markers, breast ultrasound, mammography chest X-rays and abdominal ultrasound, and CT and whole-body bone scans when necessary. The follow-up deadline of all patients was May 31, 2021. If a patient had tumor recurrence, metastasis, or death, the follow-up would be deemed as terminated. The median follow-up time was 73 months. During the follow-up period, there were 11 patients with recurrence and metastasis and 20 patients with death. The clinical and pathological characteristics such as age, menopause or not, tumor diameter, histological grade, molecular classification, lymph node metastasis, vascular invasion, radiotherapy, chemotherapy, endocrine therapy, and the location of the primary tumor were recorded.

2.6. Statistical Processing. Data processing was performed using SPSS22.0 software. The enumeration data were expressed as %, and the comparison was performed using the χ2 test. The multivariate logistic regression model was used for multivariate analysis. Kaplan–Meier survival curve was used to analyze the relationship between the location of the primary tumor and the prognosis of modified radical mastectomy. The log-rank test was used for comparison. The test level was α = 0.05, and P < 0.05 indicated that the difference was statistically significant.

3. Results

3.1. Clinical Pathological Features of IDC. Among the patients in the central region, 13.33% (2/15) had tumors >5 cm in diameter, which was higher than those in the other four groups. Among the patients in the upper inner quadrant, 59.38% (19/32) received hormone therapy postoperatively, which was higher than those in the other four groups (P < 0.05). There were no significant differences in age, menopause, histological grading, molecular classification, lymph node metastasis, vascular invasion, radiation therapy, and chemotherapy among different groups (P > 0.05) (see Table 1).

3.2. Univariate Analysis of Prognosis of IDC Patients after Modified Radical Mastectomy. Univariate analysis showed that molecular typing, lymph node metastasis, vascular invasion, and location of the primary tumor were all related to the prognosis of IDC patients after modified radical mastectomy, and the differences were statistically significant (P < 0.05) (see Table 2).

3.3. Multivariate Logistic Regression Analysis on Prognosis of IDC Patients after Modified Radical Mastectomy. Multivariate logistic regression analysis showed that molecular typing, lymph node metastasis, vascular invasion, and primary tumor location were all independent risk factors. Multivariate analysis showed that molecular typing, lymph node metastasis, vascular invasion, and the location of the primary tumor were independent risk factors for the prognosis of IDC patients after modified radical mastectomy. The hazard ratio for patients with molecular type A was 3.69 times higher than those with molecular type B (P < 0.05). Among patients with lymph node metastasis, the hazard ratio was 3.52 times higher than those without lymph node metastasis (P < 0.05). Patients with the primary tumor located in the outer upper quadrant had a significantly higher hazard ratio than those in the other four groups (P < 0.05).

Table 1: Univariate Analysis of Prognosis of IDC Patients after Modified Radical Mastectomy

| Variable              | Hazard Ratio | P-value |
|-----------------------|--------------|---------|
| Molecular classification | 3.69         | <0.05   |
| Lymph node metastasis  | 3.52         | <0.05   |
| Primary tumor location | 3.69         | <0.05   |

Table 2: Multivariate Logistic Regression Analysis on Prognosis of IDC Patients after Modified Radical Mastectomy

| Variable              | Hazard Ratio | P-value |
|-----------------------|--------------|---------|
| Molecular classification | 3.69         | <0.05   |
| Lymph node metastasis  | 3.52         | <0.05   |
| Primary tumor location | 3.69         | <0.05   |
factors for prognosis of IDC patients after modified radical mastectomy ($P < 0.05$) (see Tables 3 and 4).

3.4. The Prognostic Effect of Different Tumor Locations on IDC Patients after Modified Radical Surgery. As of 31 May 2021, there were 11 patients with recurrence and metastasis and 20 patients with death. The median survival time in the outer upper quadrant group was 80 months, which was higher than that in the outer lower quadrant group by 72 months, the median survival time in the central region group by 71 months, the median survival time in the inner upper quadrant group by 67 months, and the median survival time in the inner lower quadrant group by 61 months. The log-rank test showed all $P < 0.001$ (see Figure 1).

4. Discussion

Invasive breast cancer is a common type in breast cancer patients, and IDC is in the majority. IDC accounts for 70%–80% of invasive breast cancer, and patients are often accompanied by breast masses, pitting nipples, and other clinical manifestations [9, 10]. At present, the main examination methods of IDC include mammography, color Doppler ultrasound, CT, and MRI [11, 12]. The primary tumor is located in different locations and lymph node metastasis occurs at different rates. For early IDC patients with tumor diameter <3 cm and no axillary lymph node metastasis or only slight metastasis and no distant metastasis, the therapeutic effect is good, and more than 90% of patients can be cured for a long time [13, 14]. However, early IDC patients did not have typical clinical symptoms and signs, and it was difficult to detect them during normal times. The diagnosis needed to be made based on imaging and pathology examinations, which easily missed the optimal treatment period and posed a serious threat to women’s health [15, 16]. Therefore, early diagnosis and treatment of IDC are very important.

Among the patients in the central region, 13.33% (2/15) had tumors $>5$ cm in diameter, which was higher than those in the other four groups. Among the patients in the upper inner quadrant, 59.38% (19/32) received endocrine therapy after operation, which was higher than that in the other four groups. There were no significant differences in age, menopause or not, histological grade, molecular classification, lymph node metastasis, vascular infiltration, radiotherapy, and chemotherapy of patients among different groups. The reason for this was analyzed as the existence of a nipple-areolar complex in the central area made it difficult to detect the primary tumor, resulting in a larger tumor volume for the first detection. After the operation, the patient needs postoperative radiotherapy and chemotherapy to prevent further development of the disease [17]. Lymph node metastasis is more likely to occur in tumors in the upper inner

| Clinical pathological features | Cases ($n = 166$) | Outer upper quadrant ($n = 94$) | Outer lower quadrant ($n = 17$) | Central area ($n = 15$) | Inner upper quadrant ($n = 32$) | Inner lower quadrant ($n = 8$) | $\chi^2$ value | $P$ |
|-------------------------------|------------------|-------------------------------|-------------------------------|-------------------------|-------------------------------|-----------------------------|----------------|-----|
| Age (years)                   |                  |                               |                               |                         |                               |                             |                |     |
| $\leq 35$                      | 8                | 5                             | 1                             | 0                       | 2                             | 0                           | 0.194          | 0.986 |
| $>35$ and $<50$               | 72               | 39                            | 7                             | 7                       | 13                            | 6                           |                |     |
| $\geq 50$                     | 86               | 50                            | 9                             | 8                       | 17                            | 2                           |                |     |
| Menopause                     |                  |                               |                               |                         |                               |                             |                |     |
| No                            | 89               | 50                            | 10                            | 8                       | 17                            | 4                           | 0.983          | 0.979 |
| Yes                           | 77               | 44                            | 7                             | 7                       | 15                            | 4                           | 17.114         | 0.009 |
| Tumor diameter (cm)           |                  |                               |                               |                         |                               |                             |                |     |
| $\leq 2$                      | 43               | 17                            | 8                             | 3                       | 12                            | 3                           | 4.950          | 0.550 |
| $>2$ and $\leq 5$            | 118              | 75                            | 10                            | 9                       | 19                            | 5                           | 2.103          | 0.607 |
| $>5$                          | 5                | 2                             | 0                             | 2                       | 1                             | 0                           |                |     |
| Histological grading          |                  |                               |                               |                         |                               |                             |                |     |
| Type I                        | 7                | 4                             | 1                             | 0                       | 0                             | 2                           |                |     |
| Type II                       | 95               | 58                            | 7                             | 9                       | 18                            | 3                           |                |     |
| Type III                      | 64               | 32                            | 9                             | 6                       | 14                            | 3                           |                |     |
| Luminal A                     | 24               | 13                            | 3                             | 4                       | 4                             | 1                           |                |     |
| Luminal B                     | 81               | 46                            | 9                             | 7                       | 17                            | 2                           |                |     |
| Molecular typing              |                  |                               |                               |                         |                               |                             |                |     |
| Triple negative               | 41               | 23                            | 5                             | 5                       | 5                             | 3                           |                |     |
| Her-2 (+)                     | 20               | 12                            | 0                             | 0                       | 6                             | 2                           |                |     |
| Lymph node metastasis         |                  |                               |                               |                         |                               |                             |                |     |
| 1–3 nodes                     | 41               | 23                            | 3                             | 5                       | 8                             | 2                           |                |     |
| $\geq 4$ nodes               | 28               | 19                            | 4                             | 1                       | 4                             | 0                           |                |     |
| Vascular infiltration         |                  |                               |                               |                         |                               |                             |                |     |
| No                            | 162              | 93                            | 16                            | 14                      | 31                            | 8                           | 2.679          | 0.444 |
| Yes                           | 4                | 1                             | 1                             | 1                       | 1                             | 0                           |                |     |
| Radiation therapy             |                  |                               |                               |                         |                               |                             |                |     |
| No                            | 111              | 61                            | 12                            | 10                      | 21                            | 7                           | 0.213          | 0.975 |
| Yes                           | 55               | 33                            | 5                             | 5                       | 11                            | 1                           |                |     |
| Chemotherapy                  |                  |                               |                               |                         |                               |                             |                |     |
| No                            | 26               | 14                            | 4                             | 2                       | 6                             | 4                           | 0.515          | 0.798 |
| Yes                           | 140              | 80                            | 13                            | 13                      | 26                            | 8                           | 8.771          | 0.032 |
| Hormone therapy               |                  |                               |                               |                         |                               |                             |                |     |
| No                            | 76               | 38                            | 8                             | 11                      | 13                            | 6                           |                |     |
| Yes                           | 90               | 56                            | 9                             | 4                       | 19                            | 2                           |                |     |
quadrant, and endocrine therapy can improve endocrine function of patients, thereby avoiding the growth and metastasis of cancer cells in patients [18, 19].

Our results show that un-luminal type, multiple lymph node metastases, vascular invasion, and the location of the primary tumor in the inner quadrant are all independent risk factors for the prognosis of IDC patients after modified radical surgery. (J_he reason was analyzed as follows: IDC is a highly heterogeneous tumor, different molecular types of IDC have different biological characteristics, prognosis, and sensitivity to treatment, which affect the prognosis of patients after modified radical surgery [20, 21]. (J_he more lymph node metastasis is, the more serious the vascular invasion, which often indicates the hematogenous metastasis and lymphatic metastasis of the tumor. Therefore, the more serious the disease is, which is not conducive to the prognosis of the patient [22]. Unluminal type includes Her-2 overexpression type and triple-negative breast cancer. Although these two types are sensitive to chemotherapy, they have been found in clinical practice to have a poorer prognosis than the luminal type, which has been widely recognized in clinical practice. Lymphatic metastasis is the most common metastasis mode of IDC. The prognosis of IDC patients with primary tumors located in the central area, upper inner quadrant, and lower inner quadrant is

| Clinicopathologic features | Cases (n = 166) | 5-year survival rate | χ² value | P value |
|---------------------------|----------------|---------------------|----------|---------|
| Age (years) | | | | |
| <35 | 8 | 75.00% (6/8) | | |
| ≥35 and <50 | 72 | 83.33% (60/72) | 4.803 | 0.091 |
| ≥50 | 86 | 93.02% (80/86) | | |
| Menopause | | | | |
| No | 89 | 87.64% (78/89) | 0.018 | 0.895 |
| Yes | 77 | 88.31% (68/77) | | |
| Tumor diameter (cm) | | | | |
| >2 and ≤5 | 118 | 86.44% (102/118) | 1.596 | 0.450 |
| >5 | 5 | 80.00% (4/5) | | |
| ≤2 | 43 | 93.02% (40/43) | | |
| Histological grading | | | | |
| Type I | 7 | 100% (7/7) | | |
| Type II | 95 | 94.74% (90/95) | 0.792 | 0.782 |
| Type III | 64 | 93.75% (60/64) | | |
| Molecular typing | | | | |
| Luminal type | 105 | 92.38% (97/105) | 5.290 | 0.021 |
| Unluminal type | 61 | 80.33% (49/61) | | |
| Lymph node metastasis | | | | |
| No | 97 | 93.81% (91/97) | 8.556 | 0.000 |
| 1–3 nodes | 41 | 82.92% (34/41) | | |
| ≥4 nodes | 28 | 75.00% (21/28) | | |
| Vascular infiltration | | | | |
| No | 162 | 88.89% (144/162) | 5.472 | 0.025 |
| Yes | 4 | 50.00% (2/4) | | |
| Radiation therapy | | | | |
| No | 111 | 84.68% (94/111) | 3.375 | 0.066 |
| Yes | 55 | 94.55% (52/55) | | |
| Chemotherapy | | | | |
| No | 26 | 80.77% (21/26) | 1.501 | 0.221 |
| Yes | 140 | 89.29% (125/140) | | |
| Hormone therapy | | | | |
| No | 76 | 82.89% (63/76) | 3.383 | 0.066 |
| Yes | 90 | 92.22% (83/90) | | |
| Primary tumor location | | | | |
| Outer upper quadrant | 94 | 94.47% (89/94) | | |
| Outer lower quadrant | 17 | 88.24% (15/17) | 12.720 | 0.000 |
| Central area | 15 | 80.00% (12/15) | | |
| Inner upper quadrant | 32 | 78.13% (25/32) | | |
| Inner lower quadrant | 8 | 62.50% (5/8) | | |

| Variable | B | Wald's OR | 95% CI | P |
|----------|----|-----------|--------|---|
| Molecular typing | 0.699 | 3.028 | 1.115 | 1.142~1.825 | 0.044 |
| Lymph node metastasis | 0.758 | 2.226 | 1.652 | 1.315~1.998 | 0.032 |
| Vascular infiltration | 0.652 | 2.958 | 1.369 | 1.109~1.751 | 0.028 |
| Primary tumor location | 0.145 | 3.268 | 1.669 | 1.175~1.987 | 0.011 |

Table 2: Univariate analysis of prognosis of IDC patients after modified radical mastectomy (n, %).

Table 3: Assignment for multivariate analysis of factors.

Table 4: Multivariate logistic regression analysis on prognosis of IDC patients after modified radical mastectomy.
significantly worse than those of patients in the upper outer quadrant and lower outer quadrant. There are rich lymphatic vessels at the nipples in the central area, and the cancer cells located in the central area are easy to undergo lymphatic metastasis through the rich lymphatic vessels around, which are the independent risk factors for patients with IDC after modified radical surgery [23, 24]. The internal mammary gland is the second largest lymphatic metastasis pathway after the axillary lymph node. For IDC patients with primary tumors located in the upper inner quadrant, lower inner quadrant, and central region, the tumor was closer to the internal mammary gland lymphatic drainage pathway, and it was more prone to lymphatic metastasis, which was not conducive to the prognosis of patients [25]. In addition, internal mammary lymph nodes are characterized by deep anatomical location and small size, which are difficult to be detected clearly by mammography and color Doppler ultrasound, thus delaying the treatment time and unfavorable to the prognosis [26].

As of 31 May 2021, the median survival time in the outer upper quadrant group was 80 months, which was higher than that in the outer lower quadrant group by 72 months, the median survival time in the central region group by 71 months, the median survival time in the inner upper quadrant group by 67 months, and the median survival time in the inner lower quadrant group by 61 months. The reason was analyzed as follows: lymphatic metastasis is the most important mode of metastasis of IDC tumors. The closer the primary tumor is to the internal mammary lymphatic metastasis pathway, the more likely the cancer cells will develop lymphatic metastasis and the severer the disease will be, which will affect the prognosis of patients undergoing modified radical mastectomy [27]. As a result, the five-year survival rate of IDC patients will be reduced, and the five-year survival rate of patients with primary tumors located in the central area, the inner upper quadrant, and inner lower quadrant will be lower than that of patients located in the outer upper quadrant and outer lower quadrant. In addition, due to the excessive penetration of mammography to the nipple-areolar complex, tumors in the central region are often overlooked, requiring the combination of multiple imaging techniques [28]. The molybdenum target detection rate of breast cancer in the central region is low, and the tumor is detected in a late stage, which delays the treatment time and reduces the five-year survival rate of patients [29].

In conclusion, patients with primary tumors located in the central area have larger tumor diameters. Patients located in the central area, upper inner quadrant, and lower inner quadrant are more likely to have lymphatic metastasis, have a more serious condition, and have a shorter prognosis survival time. They are the independent risk factors for prognosis after modified radical surgery. A good understanding of IDC and timely diagnosis and treatment can effectively improve the prognosis and increase the five-year survival rate of patients.

**Data Availability**

The datasets used and/or analyzed in the current study are available from the corresponding author upon request.

**Ethical Approval**

The study was reviewed and approved by the hospital ethics committee.

**Consent**

All observed subjects and their families gave informed consent to the study.

**Disclosure**

Shiman Chen and Liang Yang are co-first authors.

**Conflicts of Interest**

The authors declare that they have no conflicts of interest.

**Authors’ Contributions**

This study was supported by the Guiding Project of Science and Technology Research Plan of Hubei Provincial Department of Education.

**References**

[1] O. Metzger-Filho, A. R. Ferreira, R. Jeselsohn et al., “Mixed invasive ductal and lobular carcinoma of the breast: prognosis and the importance of histologic grade,” *Oncologist*, vol. 24, no. 7, pp. e441–e449, 2019.

[2] F. Saadallah, I. Bouraoui, L. Naija et al., “Coexistence of invasive ductal breast carcinoma and fibroadenoma,” *Pan African Medical Journal*, vol. 33, p. 139, 2019.

[3] M. Abdel Hadi, A. Al Muhanna, J. Alratroot, and M. A. Shawarby, “Angiocentric invasive ductal carcinoma: breast images,” *Breast Journal*, vol. 26, no. 2, pp. 295-296, 2020.
[4] H. Zhao, “The prognosis of invasive ductal carcinoma, lobular carcinoma and mixed ductal and lobular carcinoma according to molecular subtypes of the breast,” Breast Cancer, vol. 28, no. 1, pp. 187–195, 2021.

[5] L. R. Lamb, G. Kim, T. O. Oseni, and M. Bah, “Noncalcified ductal carcinoma in situ (DCIS): rate and predictors of upgrade to invasive carcinoma,” Academic Radiology, vol. 28, no. 3, pp. e71–e76, 2021.

[6] L. R. Strang, J. Sun, W. Sun et al., “Characteristics of microinvasive ductal carcinoma in situ versus noninvasive and invasive breast cancer,” Journal of Surgical Research, vol. 254, pp. 378–383, 2020.

[7] N. K. Zagelbaum, M. F. Ward, N. Okby, and H. Karpoff, “Invasive ductal carcinoma of the breast with osteoclast-like giant cells and clear cell features: a case report of a novel finding and review of the literature,” World Journal of Surgical Oncology, vol. 14, no. 1, p. 227, 2016.

[8] L. Qian, X. Gao, H. Huang et al., “PRSS3 is a prognostic marker in invasive ductal carcinoma of the breast,” Oncotarget, vol. 8, no. 13, pp. 21444–21453, 2017.

[9] M. Hussain, M. Abbott, R. Zargham, A. Pabani, and O. F. Khan, “Evolution of an invasive ductal carcinoma to a small cell breast cancer: a case report,” Medicine (Baltimore), vol. 101, no. 2, Article ID e28433, 2022.

[10] T. Chakraborty, “Invasive ductal breast cancer: a retrospective study,” Anticancer Research, vol. 42, no. 1, pp. 311–320, 2022.

[11] W. A. Nehme, J. Derienne, L. E. Khoury et al., “A 58-year-old woman with acute gastric perforation due to metastatic ductal carcinoma 18 Years following bilateral mastectomy for invasive ductal carcinoma of the breast,” American Journal of Case Reports, vol. 22, Article ID e927094, 2021.

[12] C. Stroescu, I. Gilca, D. Chirita et al., “Solitary adrenal metastases from breast invasive ductal carcinoma,” Chirurgia, vol. 112, no. 4, pp. 473–476, 2017.

[13] V. Fulga, L. Rudico, A. R. Balica, A. M. Cimpean, L. Saptefrati, and M. Raica, “Invasive ductal carcinoma of no special type and its corresponding lymph node metastasis: do they have the same immunophenotypic profile?” Polish Journal of Pathology, vol. 1, pp. 30–37, 2015.

[14] R. B. Liang, K. Yu, J. L. Wu et al., “Risk factors and their diagnostic values for oculocutaneous metastases in invasive ductal carcinoma,” Cancer Medicine, vol. 10, no. 3, pp. 824–832, 2021.

[15] M. Alsaeem, M. S. Toss, C. Joseph et al., “The molecular mechanisms underlying reduced E-cadherin expression in invasive ductal carcinoma of the breast: high throughput analysis of large cohorts,” Modern Pathology, vol. 32, no. 7, pp. 967–976, 2019.

[16] Y. Wu, F. Fu, Y. Lian et al., “Monitoring the progression from intraductal carcinoma to invasive ductal carcinoma based on multiphoton microscopy,” Journal of Biomedical Optics, vol. 20, no. 9, Article ID 096007, 2015.

[17] A. P. Damin, C. L. Pozzer, T. F. Farret, A. G. Reginatto, and E. N. Trindade, “Gigantic invasive ductal carcinoma of the breast,” Breast Journal, vol. 24, no. 6, p. 1082, 2018.

[18] S. B. Dhia, I. Belaid, W. Stita, M. Hochlaf, F. Ezzairi, and S. B. Ahmed, “Bilateral parotid gland metastasis from a breast invasive ductal carcinoma,” Journal of Cancer Research and Therapeutics, vol. 16, no. 3, pp. 672–674, 2020.

[19] H. Zhang, X. Y. Ge, and H. Q. Qiao, “Analysis of prognostic risk factors in 3427 patients with invasive ductal carcinoma of breast: results based on the SEER database,” Asian Journal of Surgery, vol. 44, no. 3, pp. 577–579, 2021.